Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
10.08.2022 - -First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Non-Ambulant ...